{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:07:04Z","timestamp":1791994024138,"version":"4.4.0"},"reference-count":93,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T00:00:00Z","timestamp":1645401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Accumulating evidence supports the early use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium glucose transporter-2 inhibitors (SGLT-2is) for the treatment of type 2 diabetes. Indeed, these compounds exert numerous pleiotropic actions that favorably affect metabolism and diabetes comorbidities, showing an additional effect beyond glucose control. Although a substantial amount of knowledge has been generated regarding the mechanism of action of both drug classes, much remains to be understood. Growth hormone (GH) is an important driver for multiple endocrine responses involving changes in glucose and lipid metabolism, and affects several tissues and organs (e.g., bone, heart). It acts directly on several target tissues, including skeletal muscle and bone, but several effects are mediated indirectly by circulating (liver-derived) or locally produced IGF-1. In consideration of the multiple metabolic and cardiovascular effects seen in subjects treated with GLP-1RAs and SGLT-2is (e.g., reduction of hyperglycemia, weight loss, free\/fat mass and bone remodeling, anti-atherosclerosis, natriuresis), it is reasonable to speculate that GH and IGF-1 may play a about a relevant role in this context. This narrative mini-review aims to describe the involvement of the GH\/IGF-1\/IGF-1R axis in either mediating or responding to the effects of each of the two drug classes.<\/jats:p>","DOI":"10.3389\/fendo.2022.846903","type":"journal-article","created":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T11:00:57Z","timestamp":1645441257000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Mini Review: Effect of GLP-1 Receptor Agonists and SGLT-2 Inhibitors on the Growth Hormone\/IGF Axis"],"prefix":"10.3389","volume":"13","author":[{"given":"Angelo","family":"Cignarelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina Annamaria","family":"Genchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Le Grazie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Marrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Biondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"D\u2019Oria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Pio","family":"Sorice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Natalicchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastio","family":"Perrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Laviola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Giorgino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-014-0137-y","article-title":"GLP-1: Benefits Beyond Pancreas","volume":"37","author":"Muscogiuri","year":"2014","journal-title":"J Endocrinol Invest"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2016.52","article-title":"Effect of Liraglutide 3.0 Mg in Individuals With Obesity and Moderate or Severe Obstructive Sleep Apnea: The Scale Sleep Apnea Randomized Clinical Trial","volume":"40","author":"Blackman","year":"2016","journal-title":"Int J Obes"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA - J Am Med Assoc"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.12883","article-title":"Effect of Baseline Body Mass Index on Glycemic Control and Weight Change With Exenatide Monotherapy in Chinese Drug-Na\u00efve Type 2 Diabetic Patients","volume":"11","author":"Deng","year":"2019","journal-title":"J Diabetes"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/J.JACC.2020.02.056","article-title":"Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists: JACC Focus Seminar","volume":"75","author":"Wilcox","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00520.2015","article-title":"GLP-1 and Weight Loss: Unraveling the Diverse Neural Circuitry","volume":"310","author":"Kanoski","year":"2016","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2015.03.026","article-title":"GLP-1 Analog Liraglutide Protects Against Cardiac Steatosis, Oxidative Stress and Apoptosis in Streptozotocin-Induced Diabetic Rats","volume":"240","author":"Inoue","year":"2015","journal-title":"Atherosclerosis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1210\/JC.2017-00970","article-title":"GLP-1 Receptor Activation Inhibits Palmitate-Induced Apoptosis via Ceramide in Human Cardiac Progenitor Cells","volume":"102","author":"Leonardini","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.108667","article-title":"Glucagon-Like Peptide-1 Attenuates Endothelial Barrier Injury in Diabetes via cAMP\/PKA Mediated Down-Regulation of MLC Phosphorylation","volume":"113","author":"Tang","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.119.311904","article-title":"How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials","volume":"40","author":"Lee","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3353","article-title":"Comparative Effectiveness of Dapagliflozin vs DPP-4 Inhibitors on a Composite Endpoint of HbA1c, Body Weight and Blood Pressure Reduction in the Real World","volume":"37","author":"Morieri","year":"2021","journal-title":"Diabetes Metab Res Rev"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 Inhibitors and Mechanisms of Cardiovascular Benefit: A State-of-the-Art Review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/J.METABOL.2021.154937","article-title":"SGLT-2 Inhibitors as Cardio-Renal Protective Agents","volume":"127","author":"Caruso","year":"2021","journal-title":"Metab Clin Exp"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/DOM.14055","article-title":"Cardiovascular Protection With Sodium-Glucose Co-Transporter-2 Inhibitors in Type 2 Diabetes: Does it Apply to All Patients","volume":"22","author":"Giorgino","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1186\/S12933-020-01163-9","article-title":"Renoprotection With SGLT2 Inhibitors in Type 2 Diabetes Over a Spectrum of Cardiovascular and Renal Risk","volume":"19","author":"Giorgino","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-16-0780","article-title":"Diuretic Action of Sodium-Glucose Cotransporter 2 Inhibitors and Its Importance in the Management of Heart Failure","volume":"80","author":"Kimura","year":"2016","journal-title":"Circ J"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s11936-017-0522-x","article-title":"Promise of SGLT2 Inhibitors in Heart Failure: Diabetes and Beyond","volume":"19","author":"Martens","year":"2017","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2017.2275","article-title":"Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure - Proposal of a Novel Mechanism of Action","volume":"2","author":"Packer","year":"2017","journal-title":"JAMA Cardiol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-017-0621-8","article-title":"Dapagliflozin Acutely Improves Endothelial Dysfunction, Reduces Aortic Stiffness and Renal Resistive Index in Type 2 Diabetic Patients: A Pilot Study","volume":"16","author":"Solini","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-019-00686-z","article-title":"The Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit","volume":"10","author":"Patel","year":"2019","journal-title":"Diabetes Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2017.03.163","article-title":"Effects of Glucagon-Like Peptide-1 Receptor Agonists on Mortality and Cardiovascular Events: A Comprehensive Meta-Analysis of Randomized Controlled Trials","volume":"240","author":"Monami","year":"2017","journal-title":"Int J Cardiol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14286","article-title":"Sodium-Glucose Co-Transporter-2 Inhibitors and All-Cause Mortality: A Meta-Analysis of Randomized Controlled Trials","volume":"23","author":"Silverii","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2019.07.004","article-title":"Heterogeneity and Similarities in GLP-1 Receptor Agonist Cardiovascular Outcomes Trials","volume":"30","author":"Caruso","year":"2019","journal-title":"Trends Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154272","article-title":"Commentary: Glucose Control: Not Just a Bystander in GLP-1RA-Mediated Cardiovascular Protection","volume":"109","author":"Caruso","year":"2020","journal-title":"Metabolism"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14444","article-title":"Sodium-Glucose Co-Transporter-2 Inhibitors and Protection From Cardiovascular Death: Is It All About Heart Failure","volume":"23","author":"Caruso","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"B26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4093\/DMJ.2019.0208","article-title":"Use of SGLT-2 Inhibitors in Patients With Type 2 Diabetes Mellitus and Abdominal Obesity: An Asian Perspective and Expert Recommendations","volume":"44","author":"Wayne Huey Herng","year":"2020","journal-title":"Diabetes Metab J"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1530\/joe-18-0374","article-title":"The Key Role of a Glucagon-Like Peptide-1 Receptor Agonist in Body Fat Redistribution","volume":"240","author":"Zhao","year":"2019","journal-title":"J Endocrinol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.ej15-0749","article-title":"Ipragliflozin Effectively Reduced Visceral Fat in Japanese Patients With Type 2 Diabetes Under Adequate Diet Therapy","volume":"63","author":"Yamamoto","year":"2016","journal-title":"Endocr J"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1677\/joe-09-0431","article-title":"The GH\/IGF1 Axis and Signaling Pathways in the Muscle and Bone: Mechanisms Underlying Age-Related Skeletal Muscle Wasting and Osteoporosis","volume":"205","author":"Perrini","year":"2010","journal-title":"J Endocrinol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/3361309","article-title":"Effects of GLP-1 Receptor Agonists on Bone Mineral Density in Patients With Type 2 Diabetes Mellitus: A 52-Week Clinical Study","volume":"2021","author":"Cai","year":"2021","journal-title":"BioMed Res Int"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-016-0337-9","article-title":"Effects of Incretin-Based Therapies and SGLT2 Inhibitors on Skeletal Health","volume":"14","author":"Egger","year":"2016","journal-title":"Curr Osteoporos Rep"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/DOM.12251","article-title":"The Extra-Pancreatic Effects of GLP-1 Receptor Agonists: A Focus on the Cardiovascular, Gastrointestinal and Central Nervous Systems","volume":"16","author":"Seufert","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1186\/S12947-019-0177-8","article-title":"Effect of Sodium Glucose Cotransporter 2 Inhibitors on Cardiac Function and Cardiovascular Outcome: A Systematic Review","volume":"17","author":"Matsumura","year":"2019","journal-title":"Cardiovasc Ultrasound"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/J.METABOL.2020.154304","article-title":"Functional Loss of Pancreatic Islets in Type 2 Diabetes: How Can We Halt It","volume":"110","author":"Marrano","year":"2020","journal-title":"Metab Clin Exp"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-013-3028-4","article-title":"Exendin-4 Protects Pancreatic Beta Cells From Palmitate-Induced Apoptosis by Interfering With GPR40 and the MKK4\/7 Stress Kinase Signalling Pathway","volume":"56","author":"Natalicchio","year":"2013","journal-title":"Diabetologia"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126003","article-title":"Liraglutide Improves Pancreatic Beta Cell Mass and Function in Alloxan-Induced Diabetic Mice","volume":"10","author":"Tamura","year":"2015","journal-title":"PLoS One"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2005.11.007","article-title":"GLP-1\/Exendin-4 Facilitates \u03b2-Cell Neogenesis in Rat and Human Pancreatic Ducts","volume":"73","author":"Xu","year":"2006","journal-title":"Diabetes Res Clin Pract"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1097103","article-title":"cAMP Promotes Pancreatic Beta-Cell Survival via CREB-Mediated Induction of IRS2","volume":"17","author":"Jhala","year":"2003","journal-title":"Genes Dev"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.2337\/db09-0063","article-title":"Glucagon-Like Peptide-1 Protects Beta-Cells Against Apoptosis by Increasing the Activity of an IGF-2\/IGF-1 Receptor Autocrine Loop","volume":"58","author":"Cornu","year":"2009","journal-title":"Diabetes"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2009.10.054","article-title":"Effects of Exendin-4 on Glucose Tolerance, Insulin Secretion, and Beta-Cell Proliferation Depend on Treatment Dose, Treatment Duration and Meal Contents","volume":"390","author":"Arakawa","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.1650245","article-title":"Insulin-Like Growth Factor II in Human Fetal Pancreas and Its Co-Localization With the Major Islet Hormones: Comparison With Adult Pancreas","volume":"165","author":"Portela-Gomes","year":"2000","journal-title":"J Endocrinol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.53.suppl_3.s26","article-title":"Beta-Cell Function in Obesity: Effects of Weight Loss","volume":"53","author":"Ferrannini","year":"2004","journal-title":"Diabetes"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-0589","article-title":"Effects of Liraglutide on Weight Loss, Fat Distribution, and \u03b2-Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes","volume":"40","author":"Santilli","year":"2017","journal-title":"Diabetes Care"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1530\/jme-13-0200","article-title":"Exendin-4 Stimulates Islet Cell Replication via the IGF1 Receptor Activation of Mtorc1\/S6K1","volume":"53","author":"Xie","year":"2014","journal-title":"J Mol Endocrinol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.6065\/apem.2017.22.3.145","article-title":"Effects of Growth Hormone on Glucose Metabolism and Insulin Resistance in Human","volume":"22","author":"Kim","year":"2017","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/S41574-019-0280-9","article-title":"The Effects of Growth Hormone on Adipose Tissue: Old Observations, New Mechanisms","volume":"16","author":"Kopchick","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/dom.12398","article-title":"Albiglutide Does Not Impair the Counter-Regulatory Hormone Response to Hypoglycaemia: A Randomized, Double-Blind, Placebo-Controlled, Stepped Glucose Clamp Study in Subjects With Type 2 Diabetes Mellitus","volume":"17","author":"Hompesch","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.53.9.2397","article-title":"Effect of Intravenous Infusion of Exenatide (Synthetic Exendin-4) on Glucose-Dependent Insulin Secretion and Counterregulation During Hypoglycemia","volume":"53","author":"Degn","year":"2004","journal-title":"Diabetes"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1530\/eje-19-0171","article-title":"Effects of GLP-1 on Counter-Regulatory Responses During Hypoglycemia After GBP Surgery","volume":"181","author":"Almby","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.3.8355","article-title":"Effects of Glucagon-Like Peptide 1 on Counterregulatory Hormone Responses, Cognitive Functions, and Insulin Secretion During Hyperinsulinemic, Stepped Hypoglycemic Clamp Experiments in Healthy Volunteers","volume":"87","author":"Nauck","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/bf00581038","article-title":"Insulinotropic Actions of Intravenous Glucagon-Like Peptide-1 (GLP-1) [7?36 Amide] in the Fasting State in Healthy Subjects","volume":"32","author":"Qualmann","year":"1995","journal-title":"Acta Diabetol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2008.03510.x","article-title":"No Increased Risk of Hypoglycaemic Episodes During 48 H of Subcutaneous Glucagon-Like-Peptide-1 Administration in Fasting Healthy Subjects","volume":"71","author":"Lerche","year":"2009","journal-title":"Clin Endocrinol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1210\/jc.82.8.2423","article-title":"Changes in Bone Mineral Density, Body Composition, and Lipid Metabolism During Growth Hormone (GH) Treatment in Children With GH Deficiency","volume":"82","author":"Boot","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2013.06.029","article-title":"Increased Serum Sclerostin and Decreased Serum IGF-1 Are Associated With Vertebral Fractures Among Postmenopausal Women With Type-2 Diabetes","volume":"56","author":"Ardawi","year":"2013","journal-title":"Bone"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-2381","article-title":"Low Serum Level of the Endogenous Secretory Receptor for Advanced Glycation End Products (esRAGE) Is a Risk Factor for Prevalent Vertebral Fractures Independent of Bone Mineral Density in Patients With Type 2 Diabetes: Response to Yamamoto","volume":"33","author":"Yamagishi","year":"2010","journal-title":"Diabetes Care"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1210\/en.2007-1292","article-title":"The Murine Glucagon-Like Peptide-1 Receptor Is Essential for Control of Bone Resorption","volume":"149","author":"Yamada","year":"2007","journal-title":"Endocrinology"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01355.x","article-title":"Exenatide Treatment Did Not Affect Bone Mineral Density Despite Body Weight Reduction in Patients With Type 2 Diabetes","volume":"13","author":"Bunck","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.4158\/ep15758.or","article-title":"Comparison Of The Long-Term Effects Of Liraglutide And Glimepiride Monotherapy On Bone Mineral Density In Patients With Type 2 Diabetes","volume":"22","author":"Gilbert","year":"2016","journal-title":"Endocr Pract"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-014-0361-4","article-title":"Risk of Bone Fractures Associated With Glucagon-Like Peptide-1 Receptor Agonists\u2019 Treatment: A Meta-Analysis of Randomized Controlled Trials","volume":"48","author":"Su","year":"2014","journal-title":"Endocrine"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10209","article-title":"A Pilot Study Showing Acute Inhibitory Effect of GLP-1 on the Bone Resorption Marker CTX in Humans","volume":"3","author":"Nissen","year":"2019","journal-title":"JBMR Plus"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1898","article-title":"Exendin-4, a Glucagon-Like Peptide-1 Receptor Agonist, Prevents Osteopenia by Promoting Bone Formation and Suppressing Bone Resorption in Aged Ovariectomized Rats","volume":"28","author":"Ma","year":"2013","journal-title":"J Bone Miner Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2019.06.112","article-title":"Exendin-4 Enhances Proliferation of Senescent Osteoblasts Through Activation of the IGF-1\/IGF-1R Signaling Pathway","volume":"516","author":"Zhang","year":"2019","journal-title":"Biochem Biophys Res Commun"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181ffe4f6","article-title":"Insulin Metabolism and the Risk of Alzheimer Disease: The Rotterdam Study","volume":"75","author":"Schrijvers","year":"2010","journal-title":"Neurology"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000140291.86406.d1","article-title":"Diabetes Mellitus and Risk of Dementia in the Kungsholmen Project: A 6-Year Follow-Up Study","volume":"63","author":"Xu","year":"2004","journal-title":"Neurology"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0922","article-title":"Insulin Resistance, Brain Atrophy, and Cognitive Performance in Late Middle-Aged Adults","volume":"36","author":"Willette","year":"2013","journal-title":"Diabetes Care"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.11703","article-title":"Type 3 Diabetes Mellitus: A Link Between Alzheimer\u2019s Disease and Type 2 Diabetes Mellitus","volume":"12","author":"Nisar","year":"2020","journal-title":"Cureus"},{"key":"B67","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.neuroscience.2016.03.056","article-title":"The Role of Insulin-Like Growth Factor 1 (IGF-1) in Brain Development, Maturation and Neuroplasticity","volume":"325","author":"Dyer","year":"2016","journal-title":"Neuroscience"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1817391116","article-title":"Insulin Signaling in the Hippocampus and Amygdala Regulates Metabolism and Neurobehavior","volume":"116","author":"Soto","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.037481","article-title":"Protection and Reversal of Excitotoxic Neuronal Damage by Glucagon-Like Peptide-1 and Exendin-4","volume":"302","author":"Perry","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.300.3.958","article-title":"A Novel Neurotrophic Property of Glucagon-Like Peptide 1: A Promoter of Nerve Growth Factor-Mediated Differentiation in PC12 Cells","volume":"300","author":"Perry","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awx044","article-title":"Insulin Resistance and Exendin-4 Treatment for Multiple System Atrophy","volume":"140","author":"Bassil","year":"2017","journal-title":"Brain"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2202-13-33","article-title":"Drugs Developed to Treat Diabetes, Liraglutide and Lixisenatide, Cross the Blood Brain Barrier and Enhance Neurogenesis","volume":"13","author":"Hunter","year":"2012","journal-title":"BMC Neurosci"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.22565","article-title":"Novel GLP-1 Mimetics Developed to Treat Type 2 Diabetes Promote Progenitor Cell Proliferation in the Brain","volume":"89","author":"Hamilton","year":"2011","journal-title":"J Neurosci Res"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23320","article-title":"Multiple System Atrophy Is Associated With Changes in Peripheral Insulin-Like Growth Factor System","volume":"25","author":"Pellecchia","year":"2010","journal-title":"Mov Disord"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0567-10.2010","article-title":"Neurodegeneration in a Transgenic Mouse Model of Multiple System Atrophy Is Associated With Altered Expression of Oligodendroglial-Derived Neurotrophic Factors","volume":"30","author":"Ubhi","year":"2010","journal-title":"J Neurosci"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004962","article-title":"Neuroendocrine Disturbances in Huntington\u2019s Disease","volume":"4","author":"Saleh","year":"2009","journal-title":"PLoS One"},{"key":"B77","doi-asserted-by":"publisher","first-page":"8961","DOI":"10.1038\/s41598-018-27121-w","article-title":"Dual Therapy With Liraglutide and Ghrelin Promotes Brain and Peripheral Energy Metabolism in the R6\/2 Mouse Model of Huntington\u2019s Disease","volume":"8","author":"Duarte","year":"2018","journal-title":"Sci Rep"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173581","article-title":"Glucagon-Like Peptide-1 Cleavage Product GLP-1(9\u201336) Reduces Neuroinflammation From Stroke via the Activation of Insulin-Like Growth Factor 1 Receptor in Astrocytes","volume":"887","author":"Huang","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainresbull.2020.11.008","article-title":"Exendin-4 Induces a Novel Extended Effect of Ischemic Tolerance via Crosstalk With IGF-1r","volume":"169","author":"Zhang","year":"2021","journal-title":"Brain Res Bull"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000120505.91348.58","article-title":"Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful Reperfusion","volume":"109","author":"Nikolaidis","year":"2004","journal-title":"Circulation"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2006.08.211","article-title":"Glucagon-Like Peptide-1 Infusion Improves Left Ventricular Ejection Fraction and Functional Status in Patients With Chronic Heart Failure","volume":"12","author":"Sokos","year":"2006","journal-title":"J Card Fail"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.107.739938","article-title":"Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor\u2013Dependent and \u2013Independent Pathways","volume":"117","author":"Ban","year":"2008","journal-title":"Circulation"},{"key":"B83","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s10557-005-6892-4","article-title":"Glucagon Like Peptide-1 is Protective Against Myocardial Ischemia\/Reperfusion Injury When Given Either as a Preconditioning Mimetic or at Reperfusion in an Isolated Rat Heart Model","volume":"19","author":"Bose","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"B84","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1210\/en.2014-1519","article-title":"The Antidiabetic Hormone Glucagon-Like Peptide-1 Induces Formation of New Elastic Fibers in Human Cardiac Fibroblasts After Cross-Activation of IGF-IR","volume":"156","author":"Qa\u2019aty","year":"2015","journal-title":"Endocrinology"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/joe-19-0385","article-title":"Dapagliflozin Restores Insulin and Growth Hormone Secretion in Obese Mice","volume":"245","author":"Huang","year":"2020","journal-title":"J Endocrinol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ejphar.2016.11.028","article-title":"Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, Attenuates Obesity-Induced Inflammation in the Nodose Ganglion, Hypothalamus, and Skeletal Muscle of Mice","volume":"794","author":"Naznin","year":"2017","journal-title":"Eur J Pharmacol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2012.07.140","article-title":"IGF-I Enhances Cellular Senescence via the Reactive Oxygen Species\u2013P53 Pathway","volume":"425","author":"Handayaningsih","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1111\/j.1474-9726.2011.00704.x","article-title":"The PI3K-Akt Pathway Inhibits Senescence and Promotes Self-Renewal of Human Skin-Derived Precursors In Vitro","volume":"10","author":"Liu","year":"2011","journal-title":"Aging Cell"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1111\/acel.12219","article-title":"Insulin-Like Growth Factor-1 Regulates the SIRT1-P53 Pathway in Cellular Senescence","volume":"13","author":"Tran","year":"2014","journal-title":"Aging Cell"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqab079","article-title":"SGLT2 Inhibitors as Calorie Restriction Mimetics: Insights on Longevity Pathways and Age-Related Diseases","volume":"162","author":"Hoong","year":"2021","journal-title":"Endocrinology"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174145","article-title":"SGLT2i Increased the Plasma Fasting Glucagon Level in Patients With Diabetes: A Meta-Analysis","volume":"903","author":"Zhu","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s12020-021-02718-w","article-title":"Sodium Glucose Cotransporter 2 Inhibitors Treatment in Acromegalic Patients With Diabetes\u2014A Case Series and Literature Review","volume":"73","author":"Zaina","year":"2021","journal-title":"Endocrine"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-021-02730-0","article-title":"Growth Hormone Directly Favors Hepatic Ketogenesis in Persons With Prediabetes or Type 2 Diabetes Mellitus Treated With Empagliflozin","volume":"73","author":"da Rocha","year":"2021","journal-title":"Endocrine"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.846903\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T11:00:59Z","timestamp":1645441259000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.846903\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,21]]},"references-count":93,"alternative-id":["10.3389\/fendo.2022.846903"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.846903","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,21]]},"article-number":"846903"}}